Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beverly Moy

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Breast Cancer Research and Treatment|April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)Jennifer R Bellon, Hao Guo, William T Barry, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
Breast Cancer Research and Treatment|May 19, 2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)Kathryn J Ruddy, Hao Guo, William Barry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE TrialMina S Sedrak, Can-Lan Sun, Jingran Ji, et al.
Therapeutic Advances in Medical Oncology|September 2, 2022
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancerElyssa Denault, Erika Nakajima, Vivek Naranbhai, et al.
Contemporary Clinical Trials|July 28, 2024
Community Collaboration to Advance Racial/Ethnic Equity in Colorectal Cancer Screening: Protocol for a Multilevel Intervention to Improve Screening and Follow-up in Community Health CentersFolasade P May, Suzanne Brodney, Jessica J Tuan, et al.
Breast Cancer Research and Treatment|April 28, 2021
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimensBeverly Moy, Mafalda Oliveira, Cristina Saura, et al.
JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Breast Cancer Research and Treatment|April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)Jennifer R Bellon, Hao Guo, William T Barry, et al.
NPJ Breast Cancer|January 8, 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)Laura M Spring, Lauren Scarpetti, Arielle J Medford, et al.
Breast Cancer Research and Treatment|May 19, 2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)Kathryn J Ruddy, Hao Guo, William Barry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE TrialMina S Sedrak, Can-Lan Sun, Jingran Ji, et al.
Therapeutic Advances in Medical Oncology|September 2, 2022
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancerElyssa Denault, Erika Nakajima, Vivek Naranbhai, et al.
Contemporary Clinical Trials|July 28, 2024
Community Collaboration to Advance Racial/Ethnic Equity in Colorectal Cancer Screening: Protocol for a Multilevel Intervention to Improve Screening and Follow-up in Community Health CentersFolasade P May, Suzanne Brodney, Jessica J Tuan, et al.
Breast Cancer Research and Treatment|April 28, 2021
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimensBeverly Moy, Mafalda Oliveira, Cristina Saura, et al.
JCO Oncology Practice|November 3, 2023
Virtual Molecular and Precision Medicine Clinic to Improve Access to Clinical Trials for Patients With Metastatic Breast Cancer: An Academic/Community CollaborationLaura M Spring, Lindsey Mortensen, Elizabeth Abraham, et al.
Breast Cancer Research : BCR|March 15, 2019
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trialStephen K L Chia, Miguel Martin, Frankie A Holmes, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trialFrankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Pageof 17